Tag : CHRONICSPONTANEOUSURTICARIA

Chronic spontaneous urticaria (CSU) affects approximately 1% of the global population and is often challenging to manage. First-line treatment typically involves second-generation H1 antihistamines (H1-AH), administered at doses up to four times the standard recommendation, but only around half of patients achieve adequate symptom control. Until recently, treatment options for those who remained symptomatic were limited. This highlights an unmet need for additional targeted therapies. Recently, the United States (US) Food and Drug Administration (FDA) approved dupilumab, the first new targeted treatment for CSU in over a decade, for patients aged 12 and older who remain symptomatic despite antihistamine use.